HALO – Halozyme Therapeutics, Inc.

HALO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

11.33

Margin Of Safety %

-1

Put/Call OI Ratio

0.45

EPS Next Q Diff

0.56

EPS Last/This Y

5.46

EPS This/Next Y

1.88

Price

103.05

Target Price

99.56

Analyst Recom

1.45

Performance Q

58.18

Upside

13.7%

Beta

0.85

Ticker: HALO

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-07-14	HALO	75.06	0.39	0.02	12706
2026-07-15	HALO	75.86	0.39	0.02	12789
2026-07-16	HALO	77.57	0.39	0.99	12825
2026-07-17	HALO	77.8	0.38	0.03	12756
2026-07-20	HALO	77.07	0.39	1.08	9862
2026-07-21	HALO	78.61	0.40	0.89	10083
2026-07-22	HALO	77.83	0.40	1.01	10141
2026-07-23	HALO	80.9	0.41	0.23	10332
2026-07-24	HALO	82.13	0.41	0.42	10367
2026-07-27	HALO	81.48	0.41	0.44	10412
2026-07-28	HALO	83.49	0.41	0.61	10444
2026-07-29	HALO	83.31	0.42	0.06	10650
2026-07-30	HALO	83.28	0.41	0.12	10837
2026-07-31	HALO	82.54	0.41	0.08	10848
2026-08-03	HALO	82.27	0.41	0.25	10859
2026-08-04	HALO	83.27	0.41	0.51	10902
2026-08-05	HALO	83.58	0.41	0.08	10981
2026-08-06	HALO	90.11	0.40	0.50	11181
2026-08-07	HALO	103.05	0.45	0.11	19960
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-07-14	HALO	75.05	18.0	-	8.14
2026-07-15	HALO	75.86	18.0	-	8.14
2026-07-16	HALO	77.54	18.0	-	8.14
2026-07-17	HALO	77.79	17.1	-	8.11
2026-07-20	HALO	77.10	17.1	-	8.11
2026-07-21	HALO	78.60	17.1	-	8.11
2026-07-22	HALO	77.81	17.1	-	8.11
2026-07-23	HALO	80.87	17.1	-	8.11
2026-07-24	HALO	81.94	17.1	-	8.11
2026-07-27	HALO	81.49	17.1	-	8.11
2026-07-28	HALO	83.43	18.0	-	8.10
2026-07-29	HALO	83.32	18.0	-	8.10
2026-07-30	HALO	83.33	18.0	-	8.10
2026-07-31	HALO	82.58	18.0	-	8.10
2026-08-03	HALO	82.29	18.0	-	8.10
2026-08-04	HALO	82.29	18.0	-	8.10
2026-08-05	HALO	83.56	18.0	-	8.10
2026-08-06	HALO	85.83	18.0	-	8.10
2026-08-07	HALO	103.05	18.0	-	8.10
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-07-14	HALO	-19.04	-0.44	11.27
2026-07-15	HALO	-19.04	-0.44	11.27
2026-07-16	HALO	-19.04	-0.44	11.27
2026-07-17	HALO	-19.04	-0.44	11.27
2026-07-20	HALO	-19.04	0.21	11.27
2026-07-21	HALO	-19.04	0.21	11.27
2026-07-22	HALO	-19.04	0.21	11.27
2026-07-23	HALO	-19.04	0.21	11.27
2026-07-24	HALO	-19.04	0.21	11.27
2026-07-27	HALO	-19.04	-1.76	11.33
2026-07-28	HALO	-19.04	-1.76	11.33
2026-07-29	HALO	-19.04	-1.76	11.33
2026-07-30	HALO	-19.04	-1.76	11.33
2026-07-31	HALO	-19.04	-1.76	11.33
2026-08-03	HALO	-19.04	-2.24	11.33
2026-08-04	HALO	-19.04	-2.24	11.33
2026-08-05	HALO	-19.04	-2.24	11.33
2026-08-06	HALO	-16.32	-2.24	11.33
2026-08-07	HALO	-16.32	-2.24	11.33
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

1.6

Avg. EPS Est. Current Quarter

1.82

Avg. EPS Est. Next Quarter

2.16

Insider Transactions

-16.32

Institutional Transactions

-2.24

Beta

0.85

Average Sales Estimate Current Quarter

403

Average Sales Estimate Next Quarter

461

Fair Value

101.92

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

-19.9

Max Drawdown 5-Year %

-49.1

Target Price

99.56

P/E

30.81

Forward P/E

PEG

0.24

P/S

7.35

P/B

81.93

P/Free Cash Flow

15.17

EPS

3.35

Average EPS Est. Cur. Y

8.1

EPS Next Y. (Est.)

9.99

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

24.86

Relative Volume

4.04

Return on Equity vs Sector %

131.5

Return on Equity vs Industry %

147.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

◆ HALO Healthcare

$103.12

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

20/20

Pullback

2/25

Volume

0/15

Valuation

5/20

TP/AR

2/10

Options

8/10

RSI

87.5

Range 1M

98.4%

Sup Dist

19%

🚀

Momentum Growth

Ride accelerating trends

WATCH

Momentum

24/25

Growth

24/30

Estimates

6/20

Inst/Vol

7/15

Options

7/10

EPS Yr

101.3%

EPS NY

23.4%

52W%

98.9%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +118.5% upside

Quality

26/30

Valuation

20/30

Growth

20/25

Stability

4/10

LT Trend

4/5

Upside

+118.5%

Quality

MoS

-1%

HALO — P/E HistoricalBiotechnology

Halozyme Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 423

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

HALO

Latest News

—

Caricamento notizie per HALO…

stock quote shares HALO – Halozyme Therapeutics, Inc. Stock Price stock today

news today HALO – Halozyme Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch HALO – Halozyme Therapeutics, Inc. yahoo finance google finance

stock history HALO – Halozyme Therapeutics, Inc. invest stock market

stock prices HALO premarket after hours

ticker HALO fair value insiders trading

HALO – Halozyme Therapeutics, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: HALO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y